The Anaphase-Promoting Complex/Cyclosome (APC/C) is a multi-subunit E3 ubiquitin ligase critical for cell cycle regulation, primarily by targeting key mitotic regulators like securin and cyclin B for proteasomal degradation. ANAPC11 (APC11) is an essential catalytic subunit of the APC/C, containing a conserved RING-H2 domain that interacts with ubiquitin-conjugating enzymes (E2s) to mediate substrate ubiquitination. As a core component, ANAPC11 partners with ANAPC2 (APC2) to form the catalytic core responsible for E2 binding and ubiquitin transfer during the cell cycle.
Antibodies against ANAPC11 are vital tools for studying APC/C assembly, activity, and regulation. They enable detection of endogenous or overexpressed ANAPC11 in techniques like Western blotting, immunoprecipitation, and immunofluorescence. Researchers use these antibodies to explore APC/C’s role in mitosis, meiosis, and its dysregulation in diseases such as cancer or neurodegenerative disorders. Specific ANAPC11 antibodies can also distinguish between post-translational modifications (e.g., phosphorylation) or mutations affecting APC/C function.
Commercial ANAPC11 antibodies are typically raised against epitopes within its N-terminal or RING domains, with validation in model organisms (e.g., human, mouse). Proper controls (e.g., knockout cell lines) are recommended to confirm specificity, given APC/C’s structural complexity. Studies leveraging ANAPC11 antibodies have advanced understanding of cell cycle checkpoints, aneuploidy mechanisms, and therapeutic targeting of APC/C in proliferative diseases.